Bharat Parenterals Past Earnings Performance
Past criteria checks 0/6
Bharat Parenterals's earnings have been declining at an average annual rate of -13.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 3.5% per year.
Key information
-13.9%
Earnings growth rate
-6.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 3.5% |
| Return on equity | -8.3% |
| Net Margin | -0.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bharat Parenterals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,938 | -28 | 342 | 0 |
| 30 Jun 24 | 2,820 | 83 | 295 | 0 |
| 31 Mar 24 | 2,594 | 145 | 245 | 0 |
| 31 Dec 23 | 2,418 | 252 | 215 | 0 |
| 30 Sep 23 | 2,410 | 243 | 207 | 0 |
| 30 Jun 23 | 2,618 | 228 | 194 | 0 |
| 31 Mar 23 | 2,193 | 157 | 188 | 0 |
| 31 Dec 22 | 2,196 | 180 | 169 | 0 |
| 30 Sep 22 | 1,991 | 165 | 162 | 0 |
| 30 Jun 22 | 1,773 | 145 | 151 | 0 |
| 31 Mar 22 | 2,123 | 213 | 159 | 0 |
| 31 Dec 21 | 2,029 | 189 | 162 | 0 |
| 30 Sep 21 | 2,140 | 230 | 159 | 0 |
| 30 Jun 21 | 2,106 | 215 | 147 | 0 |
| 31 Mar 21 | 2,072 | 204 | 154 | 0 |
| 31 Dec 20 | 2,234 | 256 | 155 | 0 |
| 30 Sep 20 | 2,479 | 283 | 160 | 0 |
| 30 Jun 20 | 2,335 | 260 | 156 | 0 |
| 31 Mar 20 | 2,328 | 241 | 165 | 0 |
| 31 Dec 19 | 2,209 | 222 | 156 | 0 |
| 30 Sep 19 | 2,364 | 207 | 153 | 0 |
| 30 Jun 19 | 2,320 | 208 | 150 | 0 |
| 31 Mar 19 | 2,249 | 212 | 160 | 0 |
| 31 Dec 18 | 2,186 | 167 | 171 | 0 |
| 30 Sep 18 | 1,613 | 134 | 159 | 0 |
| 30 Jun 18 | 1,466 | 117 | 144 | 0 |
| 31 Mar 18 | 1,376 | 91 | 132 | 0 |
| 31 Dec 17 | 1,296 | 100 | 122 | 0 |
| 30 Sep 17 | 1,244 | 85 | 125 | 0 |
| 30 Jun 17 | 1,148 | 80 | 126 | 0 |
| 31 Mar 17 | 1,114 | 69 | 118 | 0 |
| 31 Dec 16 | 1,172 | 74 | 114 | 0 |
| 30 Sep 16 | 1,147 | 71 | 106 | 0 |
| 30 Jun 16 | 1,171 | 66 | 103 | 0 |
| 31 Mar 16 | 1,197 | 65 | 101 | 0 |
| 31 Mar 15 | 1,187 | 74 | 80 | 0 |
| 31 Mar 14 | 1,137 | 65 | 79 | 0 |
Quality Earnings: 541096 is currently unprofitable.
Growing Profit Margin: 541096 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 541096 is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare 541096's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 541096 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20%).
Return on Equity
High ROE: 541096 has a negative Return on Equity (-8.32%), as it is currently unprofitable.